1. Home
  2. NA vs VERU Comparison

NA vs VERU Comparison

Compare NA & VERU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

NA

Nano Labs Ltd

HOLD

Current Price

$2.00

Market Cap

58.5M

Sector

Technology

ML Signal

HOLD

Logo Veru Inc.

VERU

Veru Inc.

SELL

Current Price

$2.92

Market Cap

48.2M

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
NA
VERU
Founded
2019
1971
Country
China
United States
Employees
N/A
N/A
Industry
Semiconductors
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
58.5M
48.2M
IPO Year
2021
1996

Fundamental Metrics

Financial Performance
Metric
NA
VERU
Price
$2.00
$2.92
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$22.50
AVG Volume (30 Days)
109.3K
5.2M
Earning Date
03-30-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$16,296,958.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.58
$0.36
52 Week High
$31.48
$7.33

Technical Indicators

Market Signals
Indicator
NA
VERU
Relative Strength Index (RSI) 43.08 53.55
Support Level $1.61 $2.15
Resistance Level $2.98 $3.68
Average True Range (ATR) 0.27 0.67
MACD -0.02 -0.00
Stochastic Oscillator 17.65 16.09

Price Performance

Historical Comparison
NA
VERU

About NA Nano Labs Ltd

Nano Labs Ltd is a Web 3.0 infrastructure and product solution provider, as well as a crypto treasury company. It is focused on the development of HTC chips and HPC chips. In addition, the company has established BNB value investment and adopted BNB (a crypto token) as the primary reserve asset. Furthermore, it has launched the iPollo Claw, a dedicated hardware solution for the OpenClaw AI Agent Ecosystem. Nano Labs derives revenue mainly from its HTC and HPC offerings, which comprise Darkbird series HPC chips that feature high performance and high energy consumption efficiency, and Cuckoo series chips, used in GPUs. Geographically, the company generates maximum revenue from the People's Republic of China (PRC), and the rest from Singapore, Hong Kong, the United States, and other markets.

About VERU Veru Inc.

Veru Inc is a late clinical-stage biopharmaceutical focused on developing medicines for the treatment of cardiometabolic and inflammatory diseases. Its drug development program consists of two late-stage new chemical entities, enobosarm and sabizabulin. Enobosarm, an oral selective androgen receptor modulator, is being developed to make weight reduction by GLP-1 RA drugs more tissue selective for loss of fat and preservation of lean mass, and is planned for a Phase 2b PLATEAU clinical study in obesity. Sabizabulin, an oral microtubule disruptor, is being developed for the treatment of inflammation in atherosclerotic cardiovascular disease to lower high-sensitivity CRP in patients with stable coronary artery disease, with a planned Phase 2 study.

Share on Social Networks: